{"id":"CHEMBL102970","canonicalSmiles":"Cc1ncc(CO)c(C=O)c1O","inchiKey":"RADKZDMFGJYCBB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PYRIDOXAL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Piridoxal","Pyridoxal","Pyridoxaldehyde"],"crossReferences":{"PubChem":["170466865","26754377","29215199","29215200"],"Wikipedia":["Pyridoxal"],"drugbank":["DB00147"],"chEBI":["17310"]},"childChemblIds":["CHEMBL543846"],"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL1075788","canonicalSmiles":"CO[C@H]1C[C@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)O[C@H](C)[C@H]1O","inchiKey":"XQCGNURMLWFQJR-ZNDDOCHDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1075788","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB13240"],"chEBI":["4037"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL107874","canonicalSmiles":"CCCCCCCCCCCCC(=O)O","inchiKey":"SZHOJFHSIKHZHA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIDECANOATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tridecanoate","Tridecanoic Acid","Tridecanoic Acid Anion"],"crossReferences":{"PubChem":["144207735"],"Wikipedia":["Tridecylic_acid"],"drugbank":["DB02448"],"chEBI":["45919"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1086218","canonicalSmiles":"C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C","inchiKey":"YJDYDFNKCBANTM-QCWCSKBGSA-N","drugType":"Protein","blackBoxWarning":false,"name":"VALSPODAR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Amdray"],"synonyms":["PSC 833","SDZ PSC 833","SDZ-PSC 833","Valspodar"],"crossReferences":{"drugbank":["DB11869"],"chEBI":["8985"]},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications."}
{"id":"CHEMBL1090173","canonicalSmiles":"O=C(CO)N1CCC(c2n[nH]c(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1","inchiKey":"CATQHDWESBRRQA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SD-0006","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SD-0006","SD-06","SD0006","Sd-0006"],"crossReferences":{"PubChem":["174007108"],"drugbank":["DB07943"],"chEBI":["82712"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1096146","canonicalSmiles":"CCC/N=C1\\S/C(=C\\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C","inchiKey":"LPAUOXUZGSBGDU-STDDISTJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PONESIMOD","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ponvory"],"synonyms":["ACT-128800","Ponesimod"],"crossReferences":{"drugbank":["DB12016"]},"linkedTargets":{"rows":["ENSG00000170989"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730","MONDO_0005301","EFO_0000676"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for multiple sclerosis and has 2 investigational indications."}
{"id":"CHEMBL1096643","canonicalSmiles":"CCN(CC)CCC1(c2ccccc2)CCC(=O)NC1=O","inchiKey":"BFMBKRQFMIILCH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENGLUTARIMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phenglutarimide"],"crossReferences":{"Wikipedia":["Phenglutarimide"],"drugbank":["DB13413"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1097999","canonicalSmiles":"CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\\[C@@H](C)[C@H](C)OC2=O","inchiKey":"MWUFVYLAWAXDHQ-HMNLTAHHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"E-6201","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E-6201","E6201","ER-806201"],"crossReferences":{"drugbank":["DB11687"]},"linkedTargets":{"rows":["ENSG00000169032","ENSG00000095015"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_1001494","EFO_0000676"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL111234","canonicalSmiles":"Oc1ccc(CCc2cc(O)cc(O)c2)cc1","inchiKey":"HITJFUSPLYBJPE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIHYDRORESVERATROL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3,4',5-Trihydroxybibenzyl","Dihydro-Resveratrol","Dihydroresveratrol"],"crossReferences":{"PubChem":["537053"],"drugbank":["DB08466"],"chEBI":["4582"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200463","canonicalSmiles":"O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+]","inchiKey":"QTAQWNSMRSLSCG-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":true,"name":"OXAPROZIN POTASSIUM","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1071","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Daypro alta"],"synonyms":["Oxaprozin potassium"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200539","canonicalSmiles":"O=C([O-])[O-].[Ca+2]","inchiKey":"VTYYLEPIZMXCLO-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"CALCIUM CARBONATE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adcal","Albacar","Cacit","Cal-sup","Calc 500","Calcette","Calcichew","Calcichew fte","Calcidrink","Children's mylanta upset stomach relief","Chooz","Citrical","Mylanta soothing lozenges","Os-cal","Precipitated Calcium Carbonate","Purecal","Remegel","Rennie","Rennie fruit","Rennie gold","Setlers","Titralac","Tums"],"synonyms":["Calcii carbonas","Calcite","Calcite (ca(co3))","Calcitum","Calcium (as calcium carbonate)","Calcium (as carbonate)","Calcium carbonate","Chalk","Chalk, precipitated","Ci 77220","E-170(I)","E170","Glauberitum","Han shui shi","Hydrolyzed pearl","INS NO.170(I)","INS-170(I)","Limestone","Limestone, ground","Marble dust","NDI 443","Phx cal-carb buffer","Precipitated calcium carbonate","Precpitated calcium carbonate"],"crossReferences":{"DailyMed":["calcium%20carbonate"],"DrugCentral":["4239"],"Wikipedia":["Calcium_carbonate"],"drugbank":["DB06724"],"chEBI":["3311"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for osteoporosis and anemia (phenotype) and has 22 investigational indications."}
{"id":"CHEMBL1200761","canonicalSmiles":"COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1","inchiKey":"BFPSDSIWYFKGBC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROTRIANISENE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chlorotrianisene","Tace"],"synonyms":["Chlorotrianisene","Chlortrianisestrol","NSC-10108","Trianisestrol"],"crossReferences":{"PubChem":["104171308","11112416","11532856","124882352","144204017","144209559","144213214","170465394","17389725","26747338"],"Wikipedia":["Chlorotrianisene"],"drugbank":["DB00269"],"chEBI":["3641"]},"linkedTargets":{"rows":["ENSG00000140009"],"count":1},"linkedDiseases":{"rows":["EFO_0000182","EFO_0003843"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 2 investigational indications."}
{"id":"CHEMBL1200983","drugType":"Small molecule","blackBoxWarning":true,"name":"GALLIUM NITRATE","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ganite"],"synonyms":["Gallium nitrate","Gallium nitrate (anhydrous)","Gallium nitrate anhydrous","Gallium nitrate nonahydrate","NSC-15200","Nitric acid, gallium salt"],"crossReferences":{"DailyMed":["gallium%20nitrate"],"DrugCentral":["5115"],"Wikipedia":["Gallium_nitrate"]},"childChemblIds":["CHEMBL1697699"],"linkedTargets":{"rows":["ENSG00000171848"],"count":1},"linkedDiseases":{"rows":["EFO_0000574","Orphanet_586","EFO_0005952","EFO_0009429","EFO_0000691","EFO_0000621","EFO_1000158"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200988","canonicalSmiles":"CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-]","inchiKey":"PQMWYJDJHJQZDE-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"METHANTHELINE BROMIDE","yearOfFirstApproval":1951,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201264","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Banthine"],"synonyms":["Dixamone bromide","Methantheline bromide","Methanthelinium bromide","NSC-32145","Vagantin"],"crossReferences":{"PubChem":["144203871","170465350","56463185"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951."}
{"id":"CHEMBL1201052","canonicalSmiles":"CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21.O=S(=O)(O)c1ccccc1","inchiKey":"CRJHBCPQHRVYBS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MESORIDAZINE BESYLATE","yearOfFirstApproval":1970,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1088","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Serentil"],"synonyms":["Mesoridazine benzenesulfonate","Mesoridazine besilate","Mesoridazine besylate","NSC-760073"],"crossReferences":{"PubChem":["26719781","85273786"],"chEBI":["6781"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201138","canonicalSmiles":"Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2]","inchiKey":"KVUAALJSMIVURS-ZEDZUCNESA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"LEUCOVORIN CALCIUM","yearOfFirstApproval":1952,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1679","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calc folinate","Folacal","Fusilev","Leucovorin calcium","Leucovorin calcium preservative free","Wellcovorin"],"synonyms":["Anhydrous calcium folinate","Calcii folinas","Calcium folinate","Calcium folinate pentahydrate","Citrovorum factor","Folaren","Foliben","Folic acid related compound a","Folinate-sf calcium","Folinic acid","Folinic acid calcium salt pentahydrate","Lederfolat","Lederfolin","Leucosar","Leucovorin calcium","Leucovorin calcium pentahydrate","NSC-3590","Rescufolin","Rescuvolin","Tonofolin"],"crossReferences":{"DailyMed":["leucovorin%20calcium"],"PubChem":["538664"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 101 investigational indications."}
{"id":"CHEMBL1201353","canonicalSmiles":"CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1","inchiKey":"SOYKEARSMXGVTM-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEXCHLORPHENIRAMINE","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Chlorphenamine, (s)-","Chlorpheniramine d-form","Chlorpheniramine, (s)-","Chlorpheniramine, d-","Dapriton","Dexchlorpheniramine"],"crossReferences":{"DailyMed":["dexchlorpheniramine%20maleate"],"PubChem":["29216403","90340867"],"Wikipedia":["Dexchlorpheniramine"],"drugbank":["DB13679"],"chEBI":["4464"]},"childChemblIds":["CHEMBL1200927","CHEMBL3183101"],"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0005854","EFO_0005531","MONDO_0005301","EFO_0003958","EFO_0007533","MONDO_0005271","MONDO_0024352","EFO_0007141","EFO_0005532","EFO_1001417","MONDO_0008315","EFO_0003956"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 8 approved and 2 investigational indications."}
{"id":"CHEMBL1201461","drugType":"Small molecule","blackBoxWarning":false,"name":"DEXTROMETHORPHAN POLISTIREX","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL52440","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Delsym","Dextromethorphan polistirex"],"synonyms":["Dextromethorphan polistirex","NSC-751452"],"crossReferences":{"DailyMed":["dextromethorphan%20polistirex"]},"linkedTargets":{"rows":["ENSG00000183454","ENSG00000147955"],"count":2},"linkedDiseases":{"rows":["EFO_0003756"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication."}
{"id":"CHEMBL1201509","drugType":"Protein","blackBoxWarning":false,"name":"GONADOTROPIN, CHORIONIC","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["A.p.l.","Choragon","Chorionic gonadotropin","Equine Chorionic Gonadotropin","Follutein","Gonadotraphon lh","Human Chorionic Gonadotropin","Pregnyl","Profasi","Profast","Progestyl"],"synonyms":["Choriogonadotropin beta","Chorionic gonadotrophin","Gonadotropin, chorionic"],"crossReferences":{"DailyMed":["gonadotropin,%20chorionic"],"DrugCentral":["5196"]},"linkedTargets":{"rows":["ENSG00000138039"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730","Orphanet_64739","MONDO_0002259","EFO_0000545","MONDO_0002146","EFO_0000279","MONDO_0007254","MONDO_0002775","EFO_0004599","EFO_0000660","Orphanet_478","MONDO_0018555","EFO_0002950"],"count":13},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 9 investigational indications."}
{"id":"CHEMBL1201541","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Protamine zinc and iletin ii","Protamine zinc insulin"],"synonyms":["Insulin susp protamine zinc purified beef"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1980."}
{"id":"CHEMBL1201579","drugType":"Antibody","blackBoxWarning":false,"name":"CAPROMAB PENDETIDE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Prostascint"],"synonyms":["7E11-C5.3","CYT-351","CYT-356","Capromab pendetide"],"crossReferences":{"Wikipedia":["Indium_(111In)_capromab_pendetide"]},"description":"Antibody drug with a maximum clinical trial phase of IV that was first approved in 1996."}
{"id":"CHEMBL1201603","drugType":"Small molecule","blackBoxWarning":false,"name":"CRYPTENAMINE TANNATES","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Unitensen"],"synonyms":["Cryptenamine tannates"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201823","drugType":"Protein","blackBoxWarning":false,"name":"ABATACEPT","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Orencia","Orencia clickject"],"synonyms":["Abatacept","Abatacept (genetical recombination)","Abatacept recombinant","BMS-188667","CTLA4-IGG4M","RG-1046","RG-2077"],"crossReferences":{"DailyMed":["abatacept"],"DrugCentral":["5089"],"Wikipedia":["Abatacept"]},"linkedTargets":{"rows":["ENSG00000121594","ENSG00000114013"],"count":2},"linkedDiseases":{"rows":["EFO_0000729","EFO_1001494","EFO_0007425","EFO_0003780","EFO_0010638","EFO_0003778","EFO_0000540","EFO_1001486","EFO_1001148","EFO_0005676","EFO_0008518","EFO_0005531","EFO_0002690","MONDO_0017287","EFO_0004255","EFO_0000676","Orphanet_700","EFO_0004826","EFO_0004208","EFO_0004991","EFO_0009730","EFO_0009609","Orphanet_797","MONDO_0013730","EFO_0000685","EFO_0005761","MONDO_0001332","EFO_1001857","EFO_0003898","EFO_0003929","EFO_0000384","EFO_0004599","EFO_0002609","EFO_0000537","EFO_1001209","EFO_1001231","EFO_0000404","EFO_0004192","MONDO_0100096","MONDO_0005301","EFO_0000398","EFO_0005297","MONDO_0005147","EFO_0001378","EFO_0000699"],"count":45},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 34 investigational indications."}
{"id":"CHEMBL1230787","canonicalSmiles":"O=P(O)(O)OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H]1O","inchiKey":"KTVPXOYAKDPRHY-SQOUGZDYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1230787","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04127"],"chEBI":["40438"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232414","canonicalSmiles":"CC(=O)[C@@H](O)[C@H](O)COP(=O)(O)O","inchiKey":"AJPADPZSRRUGHI-RFZPGFLSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232414","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02496"],"chEBI":["16493"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235551","canonicalSmiles":"O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@@H]2C1","inchiKey":"FSVJFNAIGNNGKK-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRAZIQUANTEL, (R)-","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-)-praziquantel","(r)-(-)-praziquantel","(r)-praziquantel","Arpraziquantel","L-praziquantel","L-pzq","MSC-2499550A","MSC2499550A","Msc2499550a","Praziquantel, (-)-","Praziquantel, (r)-"],"crossReferences":{"PubChem":["11111633","11112791"],"drugbank":["DB11749"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235981","canonicalSmiles":"O=C(O)/C=C/c1ccc(O)cc1O","inchiKey":"HGEFWFBFQKWVMY-DUXPYHPUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(E)-2,4-Dihydroxycinnamic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(E)-2,4-Dihydroxycinnamic Acid"],"crossReferences":{"drugbank":["DB01704"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236469","canonicalSmiles":"N[C@@H](Cc1cc(I)c(O)c(I)c1)C(=O)O","inchiKey":"NYPYHUZRZVSYKL-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIOTYROSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3,5-diiodotyrosine dl-form","Diiodotyrosine","Diiodotyrosine, dl-","Dl-3,5-diiodotyrosine","Iodogorgonic acid","Jodgorgon","NSC-208959","NSC-97936"],"crossReferences":{"PubChem":["144206612","170466794","26756458","8139971"],"drugbank":["DB03374"],"chEBI":["15768"]},"childChemblIds":["CHEMBL2104305","CHEMBL2146096"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1236909","canonicalSmiles":"N[C@@H](Cc1ccc(O)c(F)c1)C(=O)O","inchiKey":"VIIAUOZUUGXERI-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1236909","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04436"],"chEBI":["46534"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1331366","canonicalSmiles":"NC(=O)Nc1ccc([As](=O)(O)O)cc1","inchiKey":"WWXBHTZSYYGCSG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBARSONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["104171295","11112267","144203955","144208247","170466507","17389993","26725287","91233"],"drugbank":["DB11382"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1378024","canonicalSmiles":"CCCc1cc(C(N)=S)ccn1","inchiKey":"VRDIULHPQTYCLN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROTIONAMIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ektebin","Peteha","Trevintix"],"synonyms":["NSC-758962","Prothionamide","Protionamide","Protionamidum","RP 9778","RP-9778","TH-1321"],"crossReferences":{"PubChem":["121269830","144205016","170465795","174006232","26749033","50085874","865168"],"drugbank":["DB12667"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for tuberculosis."}
{"id":"CHEMBL1399","canonicalSmiles":"CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1","inchiKey":"YBBLVLTVTVSKRW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANASTROZOLE","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anastrozole","Arimidex","Nastrosa"],"synonyms":["Anastrozole","Arimidex","ICI D1033","ICI-D1033","NSC-719344","NSC-759855","Rvg-106400","ZD-1033","ZD1033"],"crossReferences":{"DailyMed":["anastrozole"],"PubChem":["144205791","144213873","170464923","174007355","26719808"],"Wikipedia":["Anastrozole"],"drugbank":["DB01217"],"chEBI":["2704"]},"linkedTargets":{"rows":["ENSG00000137869"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0001361","EFO_0001065","MONDO_0007254","MONDO_0024879","EFO_0000305","HP_0000771","Orphanet_478","MONDO_0002146","MONDO_0000088","EFO_0001380","EFO_0000616","EFO_0000186","MONDO_0004658","Orphanet_562","MONDO_0008170","EFO_1001512","EFO_0000313","MONDO_0004379","MONDO_0002775","EFO_0000311","EFO_0000537","EFO_0000195","HP_0004322","EFO_0000304","GO_0007568","EFO_0000553","EFO_0006861","EFO_1001100","EFO_0005537","MONDO_0011962","EFO_0000432","EFO_1000233"],"count":33},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 21 investigational indications."}
{"id":"CHEMBL14935","canonicalSmiles":"O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1","inchiKey":"ZXFRFPSZAKNPQQ-YTWAJWBKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEZAMPANEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-293,558","LY-293558","NGX-424"],"crossReferences":{"drugbank":["DB06354"]},"childChemblIds":["CHEMBL3989703"],"linkedTargets":{"rows":["ENSG00000125675","ENSG00000120251","ENSG00000164418","ENSG00000171189","ENSG00000105737","ENSG00000149403","ENSG00000155511","ENSG00000152578","ENSG00000163873"],"count":9},"linkedDiseases":{"rows":["MONDO_0005277"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1619017","canonicalSmiles":"COc1ccc2c(c1)c1c3n2CCN(C)C3=NCC1","inchiKey":"GVXBHSBKKJRBMS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METRALINDOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Metralindole"],"crossReferences":{"PubChem":["144204537","170466367","29215095"],"drugbank":["DB09306"]},"childChemblIds":["CHEMBL1388946"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1621","canonicalSmiles":"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O","inchiKey":"PMXMIIMHBWHSKN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PALIPERIDONE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Invega","Paliperidone","Trevicta","Xeplion"],"synonyms":["9-hydroxyrisperidone","NSC-759623","Paliperidone","R-76477","RO-76477","RO76477","Risperidone impurity, 9-hydroxyrisperidone-"],"crossReferences":{"DailyMed":["paliperidone"],"PubChem":["90341688"],"Wikipedia":["Paliperidone"],"drugbank":["DB01267"],"chEBI":["83804"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000289","MONDO_0002050","HP_0000726","EFO_0000677","EFO_0003758","EFO_0005407","EFO_0001358","EFO_0004701","EFO_0004242","EFO_0005230","EFO_0005411"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1650559","canonicalSmiles":"CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O","inchiKey":"IYDYFVUFSPQPPV-PEXOCOHZSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PLAZOMICIN","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ACHN-490","Plazomicin"],"crossReferences":{"drugbank":["DB12615"]},"childChemblIds":["CHEMBL2364623"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1672","canonicalSmiles":"COCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\OC)c3csc(N)n3)[C@H]2SC1","inchiKey":"WYUSVOMTXWRGEK-HBWVYFAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFPODOXIME","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Orelox","Orelox paed"],"synonyms":["Cefpodoxime","Epoxim"],"crossReferences":{"Wikipedia":["Cefpodoxime"],"drugbank":["DB01416"],"chEBI":["3504"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for bacterial disease."}
{"id":"CHEMBL1697834","canonicalSmiles":"Cc1cc(=O)n(-c2ccccc2)n1C.OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl","inchiKey":"ATKXDQOHNICLQW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DICHLORALPHENAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dichloralantipyrine","Dichloralphenazone","Dichloralphenazone civ"],"crossReferences":{"drugbank":["DB01495"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1742998","drugType":"Antibody","blackBoxWarning":false,"name":"CANTUZUMAB RAVTANSINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cantuzumab ravtansine","HUC242-DM4","IMGN-242","IMGN242"],"linkedTargets":{"rows":["ENSG00000185499"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","MONDO_0001056","EFO_0000365","MONDO_0003219"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1743049","drugType":"Antibody","blackBoxWarning":false,"name":"OLARATUMAB","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lartruvo"],"synonyms":["IMC-3G3","IMC3G3","Olaratumab"],"crossReferences":{"DrugCentral":["5183"]},"linkedTargets":{"rows":["ENSG00000134853"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002618","EFO_0003893","EFO_0000564","Orphanet_44890","EFO_1001968","EFO_0000691","EFO_0003060","EFO_0000519","MONDO_0008315","EFO_0009708"],"count":11},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 8 investigational indications."}
{"id":"CHEMBL19019","canonicalSmiles":"O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5","inchiKey":"DQCKKXVULJGBQN-XFWGSAIBSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"NALTREXONE","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Celupan","Trexal","Trexan","Vivitrol"],"synonyms":["EN-1639A","EN-1639A FREE BASE","EN-1639A [AS HYDROCHLORIDE]","NSC-758439","Naltrexone","Revia"],"crossReferences":{"DailyMed":["naltrexone","naltrexone%20hydrochloride"],"PubChem":["144205560","170465207"],"drugbank":["DB00704"],"chEBI":["7465"]},"childChemblIds":["CHEMBL1201149","CHEMBL4303313"],"linkedTargets":{"rows":["ENSG00000082556","ENSG00000116329","ENSG00000112038"],"count":3},"linkedDiseases":{"rows":["EFO_0000729","EFO_0004240","MONDO_0005090","EFO_0002610","EFO_0005687","MONDO_0002009","EFO_0001065","EFO_0008507","MONDO_0007254","EFO_0003768","EFO_0000274","EFO_1000637","EFO_0005924","MONDO_0002046","EFO_0007191","MONDO_0005277","EFO_1000783","MONDO_0002050","MONDO_0021698","EFO_0000676","EFO_0003761","EFO_0007224","HP_0012167","HP_0003419","EFO_0004701","MONDO_0007079","MONDO_0000594","EFO_0004242","EFO_0003877","EFO_0003888","EFO_0005203","EFO_0000694","EFO_0000685","EFO_0001074","HP_0012532","HP_0012076","EFO_0004329","EFO_1000906","EFO_0000677","EFO_0001358","EFO_0010702","HP_0100716","EFO_0001073","EFO_0003843","HP_0031844","EFO_0000384","EFO_0010445","EFO_0009855","Orphanet_166","EFO_0003890","MONDO_0100096","MONDO_0005301","EFO_0000764","EFO_0004699","EFO_0005611"],"count":55},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 45 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1914489","canonicalSmiles":"CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O","inchiKey":"JWYIGNODXSRKGP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD1981","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-1981","Azd 1981","Azd-1981","Azd1981"],"crossReferences":{"drugbank":["DB11946"]},"linkedTargets":{"rows":["ENSG00000183134"],"count":1},"linkedDiseases":{"rows":["EFO_0005531","EFO_0000545","MONDO_0004979","EFO_0000341"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL194014","canonicalSmiles":"CCCOC(=O)c1ccc(O)cc1","inchiKey":"QELSKZZBTMNZEB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPYLPARABEN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E216","FEMA NO. 2951","NSC-23515","NSC-8511","Nipagin p","Nipasol","Nipazol","Paraben p","Paratexin p","Propagin","Propyl p-hydroxybenzoate","Propyl para-hydroxybenzoate","Propyl paraben","Propyl parahydroxybenzoate","Propylis hydroxybenzoas","Propylparaben","Propylparaben e216","Tegosept p"],"crossReferences":{"PubChem":["124890245","144204599","144213973","17388756","17389533","26752854","56436659"],"Wikipedia":["Propylparaben"],"drugbank":["DB14177"],"chEBI":["32063"]},"childChemblIds":["CHEMBL2107021"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL19490","canonicalSmiles":"Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1","inchiKey":"ZXVNMYWKKDOREA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZOMEPIRAC","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," United Kingdom"," United States"," Spain"," Germany "],"classes":["Immune system toxicity"],"year":1983},"tradeNames":[],"synonyms":["Zomepirac"],"crossReferences":{"PubChem":["26752779"],"Wikipedia":["Zomepirac"],"drugbank":["DB04828"],"chEBI":["35859"]},"childChemblIds":["CHEMBL3989403","CHEMBL4764346","CHEMBL266459"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for rheumatic disease. It was withdrawn in United States,  United Kingdom,  United States,  Spain and  Germany  initially in 1983 due to Immune system toxicity."}
{"id":"CHEMBL202930","canonicalSmiles":"COc1cc(-c2ccc3c(c2)NC(=O)/C3=C\\c2ccc[nH]2)ccc1O","inchiKey":"AYSXURJZVXBSRV-WJDWOHSUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"A-432411","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-432411"],"crossReferences":{"drugbank":["DB07078"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2079588","canonicalSmiles":"CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1","inchiKey":"QFCXANHHBCGMAS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TELATINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY 57-9352","BAY-579352","Bay-57-9352","Telatinib"],"crossReferences":{"PubChem":["124955475"],"drugbank":["DB15393"]},"linkedTargets":{"rows":["ENSG00000128052","ENSG00000037280","ENSG00000157404","ENSG00000113721"],"count":4},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0001056"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2103744","canonicalSmiles":"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O","inchiKey":"GRVOTVYEFDAHCL-RTSZDRIGSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MORPHINE SULFATE","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL70","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Arymo er","Astramorph pf","Avinza","Depodur","Duramorph","Duramorph pf","Duromorph","Filnarine sr","Infumorph","Kadian","Moraxen","Morcap sr","Morphabond","Morphabond er","Morphgesic sr","Morphine sulfate","Morphine sulfate (autoinjector)","Ms contin","Mst continus","Oramorph","Oramorph sr","Oramorph udv","Rhotard","Sevredol","Srm-rhotard","Zomorph"],"synonyms":["Arymo","Astramorph","Dolcontin","Kapanol","Morcap","Morphine sulfate","Morphine sulfate anhydrous","Morphine sulfate cii","Morphine sulfate hydrate","Morphine sulfate pentahydrate","Morphine sulfate,anhydrous","Morphine sulphate","Morphine sulphate anhydrous","Morphine sulphate pentahydrate","Morphini sulfas","Moscontin","NSC-11441"],"crossReferences":{"DailyMed":["morphine%20sulfate"],"PubChem":["144206414"],"chEBI":["50731"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0001361","HP_0000989","EFO_0003777","HP_0012532","Orphanet_232","EFO_0000768","HP_0003418","EFO_0003818","EFO_0010702","EFO_0003843","MONDO_0004565","EFO_0000311","EFO_0003964","EFO_0003890","EFO_0003931","EFO_1000786","EFO_0004616","HP_0003419","EFO_0000612","EFO_0005611","EFO_0005799","HP_0001822","MONDO_0024880","EFO_0003918","EFO_0005672"],"count":25},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2104047","canonicalSmiles":"C[C@H](N)C(=O)c1ccccc1","inchiKey":"PUAQLLVFLMYYJJ-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CATHINONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["C08301","Cathinone","Cathinone (incb:green list)","D-cathinone","J18.754B","Norephedrone","S-(-)-cathinone"],"crossReferences":{"PubChem":["124893451"],"drugbank":["DB01560"],"chEBI":["4110"]},"childChemblIds":["CHEMBL3182836"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2104406","canonicalSmiles":"COc1cc(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCc2cccnc2)CCCc2cccnc2)cc(OC)c1OC.O=C(O)CC(O)(CC(=O)O)C(=O)O.O=C(O)CC(O)(CC(=O)O)C(=O)O","inchiKey":"VDMKJSJJXQDICL-ZXVJYWQYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BIRICODAR DICITRATE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL350775","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Biricodar dicitrate","Incel","VX-710","VX-710-3","VX-71O-3"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2104910","canonicalSmiles":"CC(C)=CC(=O)NS(=O)(=O)c1ccc(N)cc1","inchiKey":"XRVJPLDTMUSSDE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFADICRAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Irgamid","Sulfadicramide","Sulfadicrolamide"],"crossReferences":{"drugbank":["DB13214"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2105965","canonicalSmiles":"CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21.Cl","inchiKey":"BYQDPIXWTVEVEA-JMAPEOGHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACOLBIFENE HYDROCHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL68055","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acolbifene hcl","Acolbifene hydrochloride","SCH-57068 HYDROCHLORIDE","SCH57068 HCL","SCH57068.HCL"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2106411","canonicalSmiles":"CC[C@@H](C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12","inchiKey":"SBFXHXZNBNFPHV-PXXBSISHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPICRIPTINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dihydro-.beta.-ergocryptine","Dihydro-beta-ergocryptine","Epicriptine","Epicryptine"],"crossReferences":{"drugbank":["DB11275"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106439","canonicalSmiles":"CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1","inchiKey":"KTOYYUONFQWSMW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIPOTIAZINE PALMITATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Piportil depot"],"synonyms":["19552 RP","IL-19552","Piportil","Pipothiazine","Pipotiazine","Pipotiazine palmitate","Pipotiazine palmitic ester","RP 19552","RP-19552"],"crossReferences":{"PubChem":["144206970"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for psychosis."}
{"id":"CHEMBL2107881","drugType":"Protein","blackBoxWarning":false,"name":"REGRAMOSTIM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GM-CSF","GM-CSF (CHO CELL)","GMC 89-107","GMC-89-107","Leucotropin glycoform gmc 89-107","RHGM-C","RHGM-CSF","Regramostim"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications."}
{"id":"CHEMBL2108466","drugType":"Unknown","blackBoxWarning":false,"name":"GINKGO","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B1260","Common ginkgo leaf","Common ginkgo whole","EGB 761","EGB-761","Ginkgo","Ginkgo biloba","Ginkgo biloba extract","Ginkgo biloba leaf","Ginkgo biloba leaf dry extract","Ginkgo biloba leaf extract","Ginkgo biloba leaf powder","Ginkgo biloba leaf tincture","Ginkgo biloba whole","Ginkgo biloba, ext.","Ginkgo folium","Ginkgo folium (ginkgo biloba l.)","Ginkgo leaf","Ginkgo leaf (ginkgo biloba l.)","Ginkgo macrophylla leaf","Ginkgo whole","Maidenhair tree leaf","Maidenhair tree whole","Pterophyllus salisburiensis leaf","Salisburia adiantifolia leaf","Salisburia biloba leaf","Salisburia ginkgo leaf","Salisburia macrophylla leaf","Tanakan","Tebonin forte","Tebonin intens","Tebonin spezial","Yin xing whole","Yinxingye"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."}
{"id":"CHEMBL2108589","drugType":"Antibody","blackBoxWarning":false,"name":"CLAZAKIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALD-518","ALD518","BMS-945429","Clazakizumab"],"linkedTargets":{"rows":["ENSG00000136244"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","MONDO_0100096","HP_0004326","EFO_0003778","MONDO_0004979","HP_0012378","EFO_0000384","EFO_0004599","EFO_1001904"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL2108663","drugType":"Gene","blackBoxWarning":false,"name":"VELIMOGENE ALIPLASMID","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Allovectin"],"synonyms":["Dna (plasmid vcl-1005)","Velimogene aliplasmid"],"description":"Gene drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2108764","drugType":"Unknown","blackBoxWarning":false,"name":"PROTHROMBIN COMPLEX, ACTIVATED","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Prothrombin complex, activated"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108967","drugType":"Antibody","blackBoxWarning":false,"name":"LERDELIMUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Trabio"],"synonyms":["CAT-152","Lerdelimumab","TRABIO"],"description":"Antibody drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2109396","drugType":"Antibody","blackBoxWarning":false,"name":"AMG-888","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG-888","U3-1287"],"linkedTargets":{"rows":["ENSG00000065361"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254","EFO_0003060"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109555","drugType":"Antibody","blackBoxWarning":false,"name":"MDX-070","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MDX-070"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2109566","drugType":"Antibody","blackBoxWarning":false,"name":"MEDI-557","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-557","Medi-557"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109608","drugType":"Antibody","blackBoxWarning":false,"name":"L19IL2","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L19IL2"],"linkedTargets":{"rows":["ENSG00000115414"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002618","EFO_0000756","EFO_0002617"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109615","drugType":"Antibody","blackBoxWarning":false,"name":"MRA 003 US","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MRA 003 US","Mra 003 us"],"linkedTargets":{"rows":["ENSG00000136244"],"count":1},"linkedDiseases":{"rows":["EFO_0002690"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2110559","drugType":"Small molecule","blackBoxWarning":false,"name":"TECHNETIUM PYROPHOSPHATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL1200333"],"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2110737","canonicalSmiles":"CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O","inchiKey":"HTJGLYIJVSDQAE-VWNXEWBOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CELGOSIVIR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Celgosivir"],"crossReferences":{"drugbank":["DB06580"]},"childChemblIds":["CHEMBL2105801"],"linkedTargets":{"rows":["ENSG00000257743","ENSG00000090402","ENSG00000257335","ENSG00000171298"],"count":4},"linkedDiseases":{"rows":["EFO_0005547","EFO_0004220","EFO_0000764"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2146883","canonicalSmiles":"O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1","inchiKey":"BSMCAPRUBJMWDF-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"COBIMETINIB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cotellic"],"synonyms":["Cobimetinib","GDC-0973","Gdc 0623","Gdc 0973","Gdc-0623","RG 7420","RG-7420","RG7420","Rg-7420","Rg-7421","XL-518","Xl 518","Xl518"],"crossReferences":{"DailyMed":["cobimetinib%20fumarate"],"drugbank":["DB05239"]},"childChemblIds":["CHEMBL2364607","CHEMBL3526209"],"linkedTargets":{"rows":["ENSG00000126934","ENSG00000169032"],"count":2},"linkedDiseases":{"rows":["EFO_0000756","MONDO_0007254","EFO_1000209","EFO_0000305","EFO_1001951","EFO_1001480","EFO_1000044","EFO_1000218","EFO_0000389","MONDO_0002898","EFO_1000532","EFO_0002617","EFO_0000616","EFO_1001779","MONDO_0021058","Orphanet_46724","EFO_1001956","EFO_0002916","EFO_0000503","MONDO_0008170","EFO_0000222","EFO_1000088","EFO_0003060","EFO_0000311","EFO_1001961","EFO_1000489","MONDO_0002529","EFO_0002892","EFO_0009259","EFO_0002517","MONDO_0003219","EFO_0001378","MONDO_0024880","EFO_0000691"],"count":34},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 20 investigational indications."}
{"id":"CHEMBL216146","canonicalSmiles":"Cn1c(=O)ccc2ccccc21","inchiKey":"QYEMNJMSULGQRD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL216146","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04580"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL222002","canonicalSmiles":"CCOCCC1(Oc2ccc(Oc3ccc(F)cc3)cc2)C(=O)NC(=O)NC1=O","inchiKey":"XRSYNYGEEYTXJV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL222002","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08388"],"chEBI":["45030"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL233295","canonicalSmiles":"COc1ccc(/C=C/C(=O)O)cc1O","inchiKey":"QURCVMIEKCOAJU-HWKANZROSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOFERULIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Isoferulic Acid"],"crossReferences":{"PubChem":["56314647"],"drugbank":["DB07109"],"chEBI":["27794"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL236297","canonicalSmiles":"CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(=O)c(c5oc6cc(N7CCN(CC(C)C)CC7)cc(O)c6nc-5c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C","inchiKey":"UEFHFKKWYKVLDC-HTQYORAHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIFALAZIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KRM-1648","Rifalazil"],"crossReferences":{"drugbank":["DB04934"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2364625","canonicalSmiles":"O=C([O-])C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1.[Na+]","inchiKey":"MUZRGKSNUTWRAF-BHQIMSFRSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"PRADIGASTAT SODIUM","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2364624","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LCQ-908-ABA","LCQ-908ABA","LCQ908-ABA","LCQ908A","Lcq-908 sodium salt","Lcq-908a","Lcq908a","Pradigastat sodium"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2365707","canonicalSmiles":"C[C@H](CN1CCOCC1)C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1","inchiKey":"INUNXTSAACVKJS-OAQYLSRUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2365707","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01529"],"chEBI":["74274"]},"childChemblIds":["CHEMBL2362682"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL24547","canonicalSmiles":"O=C(O)[C@H](Cc1ccccc1)N(Cc1cccc(C(F)(F)F)c1)C(=O)c1ccc(Cl)cc1Cl","inchiKey":"LAJJKGIZTCCOHY-NRFANRHFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL24547","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03605"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL24991","canonicalSmiles":"C[S+](CCC(N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O","inchiKey":"MEFKEPWMEQBLKI-YDBXVIPQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"S-ADENOSYL-L-METHIONINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["S-adenosyl-l-methionine"],"crossReferences":{"Wikipedia":["S-Adenosyl_methionine"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL254951","canonicalSmiles":"OCCS","inchiKey":"DGVVWUTYPXICAM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-MERCAPTOETHANOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Mercaptoethanol","Beta-Mercaptoethanol"],"crossReferences":{"Wikipedia":["2-Mercaptoethanol"],"drugbank":["DB03345"],"chEBI":["41218"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL260000","canonicalSmiles":"NCC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1","inchiKey":"KCWPSUKJCKZEAO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL260000","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08149"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL268869","canonicalSmiles":"COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1","inchiKey":"VLYWMPOKSSWJAL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFAMETHOXYPYRIDAZINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"year":1986},"tradeNames":["Lederkyn","Midicel","Succinylsulfathi","Sulfasuxidine"],"synonyms":["CL-13494","Depovernil","NSC-757875","Retasulphine","Sulfamethoxypyridazine","Sulfamethoxypyridazinum","Sulphamethoxypyridazine"],"crossReferences":{"PubChem":["11112213","144203924","170466374","7971832","855697"],"Wikipedia":["Sulfamethoxypyridazine"],"drugbank":["DB13773"],"chEBI":["102516"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for bacterial disease. It was withdrawn in United Kingdom  in 1986."}
{"id":"CHEMBL271220","canonicalSmiles":"CCOC[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2","inchiKey":"SLKURXRZHJOZOD-RUZDIDTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CORT 108297","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADS-108297","CORT-108297","Cort 108297"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL292439","canonicalSmiles":"CCCC[C@H](N)C(=O)O","inchiKey":"LRQKBLKVPFOOQJ-YFKPBYRVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NORLEUCINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Amino-Hexanoic Acid","Hexanoic acid, 2-amino-, (s)-","NSC-10378","Norleucine"],"crossReferences":{"drugbank":["DB15458"],"chEBI":["18347"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL307747","canonicalSmiles":"O=C(N[C@H]1CNCCC[C@H]1OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(=O)O)c(O)c1)c1ccc(O)cc1","inchiKey":"XYUFCXJZFZPEJD-PGRDOPGGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL307747","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04098"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3120215","canonicalSmiles":"COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12","inchiKey":"JROFGZPOBKIAEW-HAQNSBGRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OSI-027","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AEVI-006","ASP 7486","ASP-7486","CERC 006","CERC-006","OSI-027","Osi 027","Osi-027"],"crossReferences":{"drugbank":["DB12387"]},"linkedTargets":{"rows":["ENSG00000198793"],"count":1},"linkedDiseases":{"rows":["EFO_0000574"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL312443","canonicalSmiles":"Oc1noc2c1CCNC2","inchiKey":"ZXRVKCBLGJOCEE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GABOXADOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gaboxadol","LU 02-030","LU-02-030","LU-02030","MK-0928","NSC-759585"],"crossReferences":{"PubChem":["104171241","11111836","11111837","11113715","170466512","90341079"],"Wikipedia":["Gaboxadol"],"drugbank":["DB06554"],"chEBI":["34373"]},"childChemblIds":["CHEMBL1255746"],"linkedTargets":{"rows":["ENSG00000022355","ENSG00000109158","ENSG00000145863","ENSG00000011677","ENSG00000151834","ENSG00000145864","ENSG00000186297","ENSG00000166206","ENSG00000163288"],"count":9},"linkedDiseases":{"rows":["MONDO_0002009","Orphanet_72","EFO_0004698","Orphanet_908"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3137349","drugType":"Antibody","blackBoxWarning":false,"name":"BOCOCIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bococizumab","PF-04950615","RN-316","RN316"],"linkedTargets":{"rows":["ENSG00000169174"],"count":1},"linkedDiseases":{"rows":["HP_0003124","MONDO_0021187","EFO_0000319","EFO_0004911"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3184949","canonicalSmiles":"O=P([O-])(O)OP(=O)([O-])O.[Na+].[Na+]","inchiKey":"GYQBBRRVRKFJRG-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM ACID PYROPHOSPHATE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL1160571","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Disodium pyrophosphate","Sodium acid pyrophosphate"],"crossReferences":{"PubChem":["144208011"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3235279","canonicalSmiles":"N#Cc1c(N)nc(SCc2csc(-c3ccc(Cl)cc3)n2)c(C#N)c1-c1ccc(OCCO)cc1","inchiKey":"CITWCLNVRIKQAF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAPADENOSON","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY 68-4986","BAY-68-4986","Bay-684986","Capadenoson"],"linkedTargets":{"rows":["ENSG00000163485"],"count":1},"linkedDiseases":{"rows":["EFO_0000275","EFO_0003913"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3301612","canonicalSmiles":"COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1","inchiKey":"CMJCXYNUCSMDBY-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENCORAFENIB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Braftovi"],"synonyms":["Encorafenib","Lgx-818","Lgx818","NVP-LGX-818-NXA","NVP-LGX818","NVP-LGX818-NXA"],"crossReferences":{"DailyMed":["encorafenib"],"drugbank":["DB11718"]},"linkedTargets":{"rows":["ENSG00000157764"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0002618","EFO_0000365","EFO_0000756","EFO_0001071","EFO_0003060","EFO_0000311","EFO_1001951","EFO_1001480","EFO_1000956","EFO_0002892","EFO_0000389","EFO_0001378","MONDO_0024880","EFO_0002617"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 7 investigational indications."}
{"id":"CHEMBL331237","canonicalSmiles":"CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23","inchiKey":"HOGVTUZUJGHKPL-HTVVRFAVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRICIRIBINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-154020"],"crossReferences":{"PubChem":["144204743","170466256","26753208"],"drugbank":["DB12405"],"chEBI":["65310"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544916","canonicalSmiles":"Nc1ncn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3O)[C@@H](CO)O2)c(=O)n1","inchiKey":"GUWXKKAWLCENJA-WGWHJZDNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUADECITABINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Guadecitabine","SGI-110","Sgi-110 free acid"],"crossReferences":{"drugbank":["DB11918"]},"childChemblIds":["CHEMBL3544980"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."}
{"id":"CHEMBL3545054","drugType":"Small molecule","blackBoxWarning":false,"name":"INCB-40093","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["INCB-040093","Incb-40093"],"linkedTargets":{"rows":["ENSG00000171608"],"count":1},"linkedDiseases":{"rows":["EFO_0000183","EFO_0000311"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3545142","drugType":"Small molecule","blackBoxWarning":false,"name":"OLOCROLIMUS","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sar-943"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545333","canonicalSmiles":"CN1C(=O)C(F)=C[C@]2(C)C3CC[C@@]4(C)C(CC[C@@H]4C(=O)NCc4nc5ncccc5[nH]4)C3CCC12","inchiKey":"GBEUKTWTUSPHEE-PAWGCEJPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-0773","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mk-0773","PF-05314882"],"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["EFO_1000653"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3707353","drugType":"Small molecule","blackBoxWarning":false,"name":"RG7893","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GDC-0276","Rg7893"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL372832","canonicalSmiles":"COc1ccccc1-c1ccc(C(=O)O)o1","inchiKey":"CHWVDGYLKPLBES-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL372832","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["29215075","4242327"],"drugbank":["DB07407"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL377956","canonicalSmiles":"Nc1ccc2[nH]c(-c3cc(CC(=O)O)cc(-c4cccc([N+](=O)[O-])c4)c3O)cc2n1","inchiKey":"BVBGZXXLVHYBKI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL377956","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08232"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3833325","canonicalSmiles":"CC(=O)Oc1ccccc1C(=O)[O-].CC(=O)Oc1ccccc1C(=O)[O-].NC(N)=O.[Ca+2]","inchiKey":"VYMUGTALCSPLDM-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBASPIRIN CALCIUM","maximumClinicalTrialPhase":0,"parentId":"CHEMBL3833404","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Calcium carbaspirin","Carbasalate calcium","Carbaspirin calcium"],"crossReferences":{"DrugCentral":["4387"],"drugbank":["DB13612"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3833347","canonicalSmiles":"CC(=O)NC(CCC(=O)O)C(=O)O.CN(C)CCO","inchiKey":"WKAVKKUXZAWHDM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEANOL ACEGLUMATE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL2142890","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Deanol","Deanol aceglumate","Deanol aceglutamate","Dimethyl mea","NSC-2652","Oristar dmae"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for attention deficit hyperactivity disorder."}
{"id":"CHEMBL3833357","drugType":"Antibody","blackBoxWarning":false,"name":"BEGELOMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Begedina"],"synonyms":["BT 5/9","Begelomab","SAND-26"],"linkedTargets":{"rows":["ENSG00000197635"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730","EFO_0000540"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3989727","drugType":"Small molecule","blackBoxWarning":false,"name":"VITAMIN E","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alpha Tocopherol","Aquasol e","Bio-e-vit","Davina","E-caps","Eprolin","Fort-e-vite","Fort-e-vite 1000","Fort-e-vite plus","Fort-e-vite super plus","Harris","Jarrow for","Natopherol","Sigma","Tocopherol"],"synonyms":[".alpha.-tocopherol",".alpha.-tocopherol acetate, dl-",".alpha.-tocopherol succinate",".alpha.-tocopherol succinate, d-",".alpha.-tocopherol, d-",".alpha.-tocopheryl acetate, dl-",".alpha.-tocopheryl succinate",".alpha.-tocopheryl succinate, d-","5,7,8-trimethyltocol","All-rac-alfa-tocopheryl acetate","All-rac-alpha-tocopheryl acetate","Alpha tocopherol","Alpha-tocopherol","Alpha-tocopherol acetate, dl-","Alpha-tocopherol succinate","Alpha-tocopherol succinate, d-","Alpha-tocopherol, d-","Alpha-tocopherols","Alpha-tocopheryl acetate, dl-","D-alpha tocoferil acid succinate","D-alpha tocopherol","D-alpha-tocopherol","Dl-.alpha.-tocopherol acetate","Dl-.alpha.-tocopheryl acetate","Dl-alpha tocopheryl acetate","Dl-alpha-tocopheryl acetate","E-307A","Envirose 100","INS NO.307A","INS-307A","J203.513H","J24.260H","J24.824J","J262.912G","NSC-173849","NSC-20812","R,r,r-.alpha.-tocopherol","Rrr-alpha-tocopherol concentrate","Tocopherol","Tocopherol (vit e)","Tocopherol succinate","Tocopherol, d-alpha-","Tocopheryl acetate, d-alpha","Tocopheryl acetate, dl-.alpha.","Tocopheryl acetate, dl-alpha","Tocopheryl acetate,dl-alpha","Tocopheryl acid succinate","Tocopheryl acid succinate, d-alpha","Tocopheryl succinate","Vitamin e","Vitamin e (as alpha tocopherol)","Vitamin e d-alpha","Vitamin e hemisuccinate","Vitamin e succinate","Vitamin e, unspecified form","Vitamine e succinate"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 68 investigational indications."}
{"id":"CHEMBL3989932","canonicalSmiles":"CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O","inchiKey":"VBTZKFAHKJXHBA-PIONDTTLSA-N","drugType":"Protein","blackBoxWarning":false,"name":"ANGIOTENSIN II ACETATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL408403","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Giapreza"],"synonyms":["Angiotensin ii acetate","Angiotensin ii acetate human","Angiotensin ii triacetate"],"crossReferences":{"DailyMed":["angiotensin%20ii%20acetate"]},"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["EFO_0006834"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for septic shock."}
{"id":"CHEMBL3990000","drugType":"Antibody","blackBoxWarning":false,"name":"TIBULIZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-3090106","LY3090106","Tibulizumab"],"linkedTargets":{"rows":["ENSG00000102524","ENSG00000112115"],"count":2},"linkedDiseases":{"rows":["EFO_0000685","EFO_0000699"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3991035","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM STIBOGLUCONATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL2079699"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for leishmaniasis and trypanosomiasis and has 6 investigational indications."}
{"id":"CHEMBL402761","canonicalSmiles":"O=C(Nc1ccccc1S(=O)(=O)Nc1ccc(Cl)cn1)c1ccc(-n2ccccc2=O)cc1","inchiKey":"MIJGLXFQYBTIFY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL402761","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07800"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL404","canonicalSmiles":"C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O","inchiKey":"LPQZKKCYTLCDGQ-WEDXCCLWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAZOBACTAM","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["CL 298,741","CL-298741","NSC-759887","Tazobactam","YTR-830H"],"crossReferences":{"DailyMed":["tazobactam%20sodium"],"Wikipedia":["Tazobactam"],"drugbank":["DB01606"],"chEBI":["9421"]},"childChemblIds":["CHEMBL1439"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 10 approved and 20 investigational indications."}
{"id":"CHEMBL4078588","canonicalSmiles":"Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1","inchiKey":"JUVQLZBJFOGEEO-GOTSBHOMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-7622","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK7622","Mk-7622"],"crossReferences":{"drugbank":["DB12897"]},"childChemblIds":["CHEMBL4216833"],"linkedTargets":{"rows":["ENSG00000168539"],"count":1},"linkedDiseases":{"rows":["MONDO_0004975"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL41355","canonicalSmiles":"CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N","inchiKey":"PCOBBVZJEWWZFR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"EZOGABINE","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Potiga","Trobalt"],"synonyms":["AWD-21360","AWD21-360","D-23129","Ezogabine","GKE-841","GW-582892X","GW582892X","Retigabine","WAY-143841"],"crossReferences":{"PubChem":["174006313"],"Wikipedia":["Retigabine"],"drugbank":["DB04953"],"chEBI":["68584"]},"linkedTargets":{"rows":["ENSG00000053918","ENSG00000117013","ENSG00000184156","ENSG00000185760","ENSG00000075043"],"count":5},"linkedDiseases":{"rows":["EFO_0000474","MONDO_0002050","MONDO_0041052","MONDO_0002009","HP_0001250","MONDO_0004976"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for epilepsy and seizure and has 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4208954","canonicalSmiles":"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O","inchiKey":"FXKSEJFHKVNEFI-GCZBSULCSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"AMIKACIN SULFATE","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL177","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amiglyde","Amikacin sulfate","Amikin","Arikayce kit"],"synonyms":["Amikacin (as sulfate)","Amikacin sulfate","Amikacin sulphate","Amikacini sulfas","Arikayce","BB-K8","NSC-755846"],"crossReferences":{"DailyMed":["amikacin%20sulfate"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4280145","canonicalSmiles":"Oc1cc2c(cc1O)[C@@H]1c3ccccc3CN[C@H]1CC2","inchiKey":"BGOQGUHWXBGXJW-YOEHRIQHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL4280145","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB12890"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297091","canonicalSmiles":"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O.O=S(=O)(O)O","inchiKey":"BOLDZXRCJAJADM-AAXBYHQXSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CODEINE SULFATE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL485","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Codeine sulfate"],"synonyms":["Codeine sulfate","Codeine sulfate anhydrous","Codeine sulfate cii","Codeine sulfate trihydrate","Codeine sulphate"],"crossReferences":{"DailyMed":["codeine%20sulfate"]},"linkedTargets":{"rows":["ENSG00000082556","ENSG00000116329","ENSG00000112038"],"count":3},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for pain. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4297201","drugType":"Small molecule","blackBoxWarning":false,"name":"CHROMIUM PICOLINATE","maximumClinicalTrialPhase":1,"parentId":"CHEMBL3185022","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Chromium picolinate"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297236","drugType":"Gene","blackBoxWarning":false,"name":"LISOCABTAGENE MARALEUCEL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JCAR-017","JCAR017","Lisocabtagene maraleucel"],"linkedTargets":{"rows":["ENSG00000177455"],"count":1},"linkedDiseases":{"rows":["EFO_0000095","EFO_0000220","EFO_0000403","MONDO_0018906","EFO_1001469","EFO_0005952"],"count":6},"description":"Gene drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL4297435","canonicalSmiles":"COC(=O)c1nc(C(F)(F)F)n2c1CN(C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)CC2","inchiKey":"WIIAMRXFUJLYEF-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RETAGLIPTIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Retagliptin","SP-2086","SP2086","Sp2086"],"crossReferences":{"drugbank":["DB14898"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297523","canonicalSmiles":"COc1ccc2[nH]cc(CCNC(=O)c3cc(=O)cco3)c2c1","inchiKey":"PNTNBIHOAPJYDB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIROMELATINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NEU-P-11","NEU-P11","Neu-p11","Piromelatine"],"crossReferences":{"drugbank":["DB12288"]},"linkedTargets":{"rows":["ENSG00000168412","ENSG00000134640"],"count":2},"linkedDiseases":{"rows":["MONDO_0004975","EFO_0004698"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297525","canonicalSmiles":"NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1","inchiKey":"KUBPNVYPKPWGRJ-LIVOIKKVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RELAMORELIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIM-28131","BIM28131","Relamorelin"],"crossReferences":{"drugbank":["DB12678"]},"linkedTargets":{"rows":["ENSG00000121853"],"count":1},"linkedDiseases":{"rows":["EFO_1000948"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL4297592","canonicalSmiles":"Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1","inchiKey":"MNHNIVNAFBSLLX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMENAMEVIR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ASP-2151","ASP2151","Amenamevir","Asp2151"],"crossReferences":{"drugbank":["DB11701"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297655","canonicalSmiles":"CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC/C=C\\CCCCCCCC)OC(=O)CCCCCCCCCCC/C=C\\CCCCCCCC","inchiKey":"XDSPGKDYYRNYJI-IUPFWZBJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLYCERYL TRIERUCATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["13-docosenoin, tri-, (z,z,z)-","Erucic acid triglyceride","Erucin, tri-","Glycerol trierucate","Glyceryl trierucate","Tri(z-13-docosenoyl)glycerol","Trierucin"],"crossReferences":{"drugbank":["DB12528"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL4298094","drugType":"Unknown","blackBoxWarning":false,"name":"ARCHEXIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Archexin","RX-0201","RX-201","Rx-0201"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298193","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"SUVODIRSEN SODIUM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMTR0139 SODIUM","Suvodirsen sodium","WLS-4176 SODIUM","WV3473"],"description":"Oligonucleotide drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4298205","drugType":"Antibody","blackBoxWarning":false,"name":"ETIGILIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Etigilimab","OMP-313M32"],"linkedTargets":{"rows":["ENSG00000181847"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0024880"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL430145","canonicalSmiles":"C/C=C1/C(=O)N[C@@H](C(=O)O)[C@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](/C=C/C(C)=C/[C@H](C)[C@H](Cc2ccccc2)OC)[C@H](C)C(=O)N[C@@H](C(=O)O)CCC(=O)N1C","inchiKey":"GIRIHYQVGVTBIP-NJYUBDSESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOTUPORIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Motuporin"],"crossReferences":{"drugbank":["DB04738"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL435747","canonicalSmiles":"Nc1ncccc1NCc1ccccc1","inchiKey":"MUKAGFLFIMVSQN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL435747","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07281"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL44833","canonicalSmiles":"N=C(NCCC[C@H](N)C(=O)N[C@@H](CCN)C(N)=O)N[N+](=O)[O-]","inchiKey":"KUZKVXUOMSVPOA-BQBZGAKWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL44833","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["29217600"],"drugbank":["DB01821"]},"childChemblIds":["CHEMBL481413","CHEMBL1204421"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL455907","canonicalSmiles":"C[C@H](NC1=NC(=O)[C@](C)(C(C)(C)O)S1)c1ccc(F)cc1","inchiKey":"HYVZYASDRIAOPU-BJOHPYRUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL455907","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07017"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594465","drugType":"Unknown","blackBoxWarning":false,"name":"BI-1206","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-hfcgammariib mab bi-1206","BI-1206","BI1206","Bi-1206","Bi1206"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4594487","drugType":"Unknown","blackBoxWarning":false,"name":"PF-06688992","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-06688992","Pf-06688992"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594578","drugType":"Antibody","blackBoxWarning":false,"name":"TEBOTELIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mgd 013","Mgd-013","Mgd013","Mgd013 (pd-1 x lag-3)","Tebotelimab"],"linkedTargets":{"rows":["ENSG00000188389","ENSG00000089692"],"count":2},"linkedDiseases":{"rows":["MONDO_0001056","EFO_0000182","EFO_1001512","MONDO_0007254","EFO_0000181"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4594612","drugType":"Antibody","blackBoxWarning":false,"name":"BEPRANEMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bepranemab","UCB-0107","UCB0107","Ucb0107"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4650256","drugType":"Antibody","blackBoxWarning":false,"name":"ZANIDATAMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ZW-25","Zanidatamab"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL47527","canonicalSmiles":"Cc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1","inchiKey":"JJDRRZFRTKZLFT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL47527","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04518"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4802158","canonicalSmiles":"C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@@]21C","inchiKey":"PIUZYOCNZPYXOA-ZHHJOTBYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LARSUCOSTEROL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["25HC3S","DUR-928","DV-928","Dur-928","Larsucosterol"],"childChemblIds":["CHEMBL4802246"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL483716","canonicalSmiles":"CCC1=C[C@@H]2Cc3nc4cc(Cl)ccc4c(N)c3[C@H](C1)C2","inchiKey":"QTPHSDHUHXUYFE-NWDGAFQWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL483716","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04114"]},"childChemblIds":["CHEMBL1684446"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL504111","canonicalSmiles":"CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc([18F])cc1)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N)=O)[C@@H](C)O)C(C)C)C(C)C","inchiKey":"LXFYUKLDFCXXMA-IBQCUMGVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"[18F]-FBA-A20FMDV2","maximumClinicalTrialPhase":1,"parentId":"CHEMBL1908904","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["[18f]-fba-a20fmdv2"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL527066","canonicalSmiles":"Nc1cc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccn1","inchiKey":"USBSTVPJNQLYEM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL527066","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06995"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL589370","canonicalSmiles":"Nc1cccc2c(S(=O)(=O)O)cccc12","inchiKey":"DQNAQOYOSRJXFZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL589370","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07176"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL59356","canonicalSmiles":"C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O","inchiKey":"MMSNEKOTSJRTRI-LLVKDONJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATRELEUTON","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A-85761","A-85761.0","ABBOTT-85761","ABT-761","Atreleuton","VIA-2291"],"crossReferences":{"drugbank":["DB12758"]},"linkedTargets":{"rows":["ENSG00000012779"],"count":1},"linkedDiseases":{"rows":["EFO_0003914","EFO_0001645","EFO_0005672"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL596186","canonicalSmiles":"Nc1ccn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]2O)c(=O)n1","inchiKey":"IERHLVCPSMICTF-CCXZUQQUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARA-5'-CMP","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ara-5'-cmp","Ara-cytidine monophosphate","Aracmp","Aracytidine 5'-monophosphate","Aracytidine 5'-phosphate","Cytarabine 5'-phosphate","NSC-99445","cytarabine"],"crossReferences":{"drugbank":["DB02456"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL607707","canonicalSmiles":"CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C","inchiKey":"WVUNYSQLFKLYNI-AATRIKPKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PELITINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EKB-569","Pelitinib","WAY-EKB-569"],"crossReferences":{"PubChem":["50100098"],"drugbank":["DB05524"],"chEBI":["38927"]},"linkedTargets":{"rows":["ENSG00000146648"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_1000657","EFO_0003060","EFO_0004288"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL638","canonicalSmiles":"C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F","inchiKey":"BCEHBSKCWLPMDN-MGPLVRAMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VORICONAZOLE","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vfend","Voriconazole"],"synonyms":["NSC-759888","UK-109,496","UK-109496","Vfend","Voriconazole"],"crossReferences":{"DailyMed":["voriconazole"],"PubChem":["144205794","170464890","26719857"],"Wikipedia":["Voriconazole"],"drugbank":["DB00582"],"chEBI":["10023"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 15 investigational indications."}
{"id":"CHEMBL701","canonicalSmiles":"NCC(CC(=O)O)c1ccc(Cl)cc1","inchiKey":"KPYSYYIEGFHWSV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"BACLOFEN","yearOfFirstApproval":1977,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Baclofen","Baclospas-10","Gablofen","Kemstro","Lioresal","Lioresal intrath","Lyflex","Ozobax"],"synonyms":["(rs)-baclofen","BA-34,647","BA-34647","Baclofen","NSC-755906"],"crossReferences":{"DailyMed":["baclofen"],"PubChem":["104171115","124879423","124879424","170465099","26751712","50104402","85230940","855960","90341690"],"Wikipedia":["Baclofen"],"drugbank":["DB00181"],"chEBI":["2972"]},"childChemblIds":["CHEMBL1897150"],"linkedTargets":{"rows":["ENSG00000136928","ENSG00000204681"],"count":2},"linkedDiseases":{"rows":["EFO_1000802","HP_0001257","EFO_0004777","EFO_0002610","HP_0002063","EFO_0009488","EFO_1001919","EFO_0003758","EFO_0003768","EFO_0001073","EFO_0003843","EFO_0009857","Orphanet_908","EFO_0007191","EFO_0003948","Orphanet_166","EFO_0003890","EFO_0000512","MONDO_0005301","EFO_0000182","EFO_1000632","HP_0003419","MONDO_0043510","MONDO_0007079"],"count":24},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 7 approved and 14 investigational indications. This drug has a black box warning from the FDA."}
